Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

AFIP GIST Risk (Miettinen)

The AFIP (Miettinen) criteria improve upon the NIH criteria by incorporating tumor location (Stomach, Duodenum, Jejunum/Ileum, Rectum), recognizing that gastric GISTs generally have a better prognosis than intestinal GISTs of similar size/grade.

Evidence-based context for fast calculator use

Purpose:
AFIP Miettinen criteria stratify GIST progression risk by tumor size, mitotic rate, and anatomic location to guide surveillance and treatment.
Population:
patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model
Factors:
Tumor Location, Tumor Size, Mitotic Count
Reference:
Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83.
HomeAFIP GIST Risk (Miettinen)
Pin your most used calculators here by clicking the star in the dropdown.

AFIP GIST Risk (Miettinen)

Clinical Context & Background

The AFIP (Miettinen) criteria improve upon the NIH criteria by incorporating tumor location (Stomach, Duodenum, Jejunum/Ileum, Rectum), recognizing that gastric GISTs generally have a better prognosis than intestinal GISTs of similar size/grade.
Primary Source EvidenceMiettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83.
Formula Logic
Risk of progression % based on Size, Mitoses, and Site.

Reference Data

Risk GroupRisk of Progression
None0%
Very Low1 - 10%
Moderate10 - 30%
High> 30%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use AFIP GIST Risk (Miettinen) when aFIP Miettinen criteria stratify GIST progression risk by tumor size, mitotic rate, and anatomic location to guide surveillance and treatment.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning None through High.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm primary site, histology, stage, surgery status, systemic-treatment timing, and disease-specific guideline before applying the result.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not transfer thresholds across colorectal, GIST, gastric, appendiceal, and other peritoneal malignancies.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model

How to apply this result

For a representative case, verify Tumor Location, Tumor Size, Mitotic Count, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

GI, GIST & Peritoneal hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

Modified Glasgow Prognostic Score (mGPS)Fong Clinical Risk Score (CRS)Peritoneal Carcinomatosis Index (PCI)

Frequently Asked Questions

When should AFIP GIST Risk (Miettinen) be used?

Use it for patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model when all required inputs and the intended clinical setting are confirmed.

Can AFIP GIST Risk (Miettinen) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.